Digital Adherence Technologies and Differentiated Care for Tuberculosis Treatment and Their Acceptability Among Persons With Tuberculosis, Health Care Workers, and Key Informants in the Philippines: Qualitative Interview Study.

Philippines acceptability digital adherence digital adherence technologies digital health health care workers implementation interview interviews medication adherence privacy qualitative research support support strategy tuberculosis tuberculosis treatment user user privacy

Journal

JMIR human factors
ISSN: 2292-9495
Titre abrégé: JMIR Hum Factors
Pays: Canada
ID NLM: 101666561

Informations de publication

Date de publication:
23 Jul 2024
Historique:
received: 18 11 2023
accepted: 01 05 2024
revised: 25 04 2024
medline: 23 7 2024
pubmed: 23 7 2024
entrez: 23 7 2024
Statut: epublish

Résumé

Digital adherence technologies (DATs) are being studied to determine their potential to support tuberculosis (TB) treatment and address the shortcomings of directly observed therapy. Previous research has shown inconclusive results on whether DATs can enhance medication adherence among persons with TB. This study aims to understand the acceptability of DATs, namely, medication labels and smart pillboxes, among persons with TB, health care workers (HCWs), and key informants (KIs) in the Philippines. The objective is to gain valuable insights that can inform the design and implementation of DATs in the Southeast Asian region, which meet the needs and preferences of end users. Persons with TB, HCWs, and KIs were recruited from intervention facilities to participate in in-depth interviews conducted between March 2022 and January 2023. These interviews were transcribed and translated into English. A thematic analysis was carried out using NVivo software (Lumivero) to identify and analyze themes. Themes were then structured within a modified social-ecological model. A total of 25 persons with drug-sensitive TB and 20 HCWs or KIs were interviewed. Both groups emphasized that users' technology literacy level, financial conditions, and motivation to be cured determined how they interacted with the DAT. They also acknowledged that DATs helped foster their relationship with HCWs and enabled efficient treatment support. Concerning technology, persons with TB found DATs easy to use and able to reduce clinic visits. HCWs mentioned that DATs added to their workload but also allowed them to support users who missed doses. However, both groups experienced technical challenges with DATs. Regarding program implementation, users appreciated the clear explanations and demonstrations provided by HCWs. Yet, some users reported inconsistencies between DAT settings and the information provided. HCWs stressed the importance of comprehensive training and sufficient resources for effective program implementation in the future. At the community level, both groups noted that DATs and program design protected users' privacy and reduced the risk of stigma. Finally, users and HCWs shared various contextual factors that influenced their experience with DAT, including infrastructure challenges and the impact of the COVID-19 pandemic. In the Philippines, persons with TB and HCWs showed a high level of acceptance and satisfaction with the impact of DAT and program design. They expressed a desire for the continuation of DATs. The challenges encountered underscore the need for ongoing technological development to minimize malfunctions, enhance the capacity of health facilities, and improve infrastructure. DATs have demonstrated their ability to strengthen user-HCW relationships and protect users from stigmatization. Additional efforts are required to scale up the DAT program in the Philippines.

Sections du résumé

BACKGROUND BACKGROUND
Digital adherence technologies (DATs) are being studied to determine their potential to support tuberculosis (TB) treatment and address the shortcomings of directly observed therapy. Previous research has shown inconclusive results on whether DATs can enhance medication adherence among persons with TB.
OBJECTIVE OBJECTIVE
This study aims to understand the acceptability of DATs, namely, medication labels and smart pillboxes, among persons with TB, health care workers (HCWs), and key informants (KIs) in the Philippines. The objective is to gain valuable insights that can inform the design and implementation of DATs in the Southeast Asian region, which meet the needs and preferences of end users.
METHODS METHODS
Persons with TB, HCWs, and KIs were recruited from intervention facilities to participate in in-depth interviews conducted between March 2022 and January 2023. These interviews were transcribed and translated into English. A thematic analysis was carried out using NVivo software (Lumivero) to identify and analyze themes. Themes were then structured within a modified social-ecological model.
RESULTS RESULTS
A total of 25 persons with drug-sensitive TB and 20 HCWs or KIs were interviewed. Both groups emphasized that users' technology literacy level, financial conditions, and motivation to be cured determined how they interacted with the DAT. They also acknowledged that DATs helped foster their relationship with HCWs and enabled efficient treatment support. Concerning technology, persons with TB found DATs easy to use and able to reduce clinic visits. HCWs mentioned that DATs added to their workload but also allowed them to support users who missed doses. However, both groups experienced technical challenges with DATs. Regarding program implementation, users appreciated the clear explanations and demonstrations provided by HCWs. Yet, some users reported inconsistencies between DAT settings and the information provided. HCWs stressed the importance of comprehensive training and sufficient resources for effective program implementation in the future. At the community level, both groups noted that DATs and program design protected users' privacy and reduced the risk of stigma. Finally, users and HCWs shared various contextual factors that influenced their experience with DAT, including infrastructure challenges and the impact of the COVID-19 pandemic.
CONCLUSIONS CONCLUSIONS
In the Philippines, persons with TB and HCWs showed a high level of acceptance and satisfaction with the impact of DAT and program design. They expressed a desire for the continuation of DATs. The challenges encountered underscore the need for ongoing technological development to minimize malfunctions, enhance the capacity of health facilities, and improve infrastructure. DATs have demonstrated their ability to strengthen user-HCW relationships and protect users from stigmatization. Additional efforts are required to scale up the DAT program in the Philippines.

Identifiants

pubmed: 39042889
pii: v11i1e54117
doi: 10.2196/54117
doi:

Substances chimiques

Antitubercular Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e54117

Informations de copyright

©Chung Lam Leung, Jason Alacapa, Bianca Gonçalves Tasca, Andre Daniel Villanueva, Saniata Masulit, Marvin Louie Ignacio, Kathleen Nicole Uy, Christopher Pell, Kristian van Kalmthout, Rachel Powers, Katherine Fielding, Degu Jerene. Originally published in JMIR Human Factors (https://humanfactors.jmir.org), 23.07.2024.

Auteurs

Chung Lam Leung (CL)

KNCV Tuberculosis Foundation, Den Haag, Netherlands.

Jason Alacapa (J)

KNCV Tuberculosis Foundation Philippines, Metro Manila, Philippines.

Bianca Gonçalves Tasca (BG)

KNCV Tuberculosis Foundation, Den Haag, Netherlands.

Andre Daniel Villanueva (AD)

KNCV Tuberculosis Foundation Philippines, Metro Manila, Philippines.

Saniata Masulit (S)

KNCV Tuberculosis Foundation Philippines, Metro Manila, Philippines.

Marvin Louie Ignacio (ML)

KNCV Tuberculosis Foundation Philippines, Metro Manila, Philippines.

Kathleen Nicole Uy (KN)

KNCV Tuberculosis Foundation Philippines, Metro Manila, Philippines.

Christopher Pell (C)

KNCV Tuberculosis Foundation, Den Haag, Netherlands.

Kristian van Kalmthout (K)

KNCV Tuberculosis Foundation, Den Haag, Netherlands.

Rachel Powers (R)

KNCV Tuberculosis Foundation, Den Haag, Netherlands.

Katherine Fielding (K)

TB Centre and Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, United Kingdom.

Degu Jerene (D)

KNCV Tuberculosis Foundation, Den Haag, Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH